Information not publicly detailed
Various
Not DisclosedActive
Key Facts
About Elpen Pharmaceutical
Elpen Pharmaceutical is a prominent, privately-held Greek pharmaceutical company with over 80 years of history, operating primarily in the branded generics sector while pursuing innovative drug development. It leverages its strong manufacturing base and distribution network in Greece to serve broader European and international markets. The company's strategy combines the stable revenue from its generic portfolio with the growth potential of its proprietary R&D pipeline. As a major player in the Greek healthcare sector, Elpen's outlook is tied to regional market dynamics, regulatory changes, and its ability to advance its innovative programs.
View full company profileTherapeutic Areas
Other Various Drugs
| Drug | Company | Phase |
|---|---|---|
| New Generic Approvals | China SXT Pharmaceuticals | Application Submitted / BE Stage |
| New Dosage Form Development | Universe Pharmaceuticals | Development |
| New TCM Formula Registration | Universe Pharmaceuticals | Development |
| CBD/THC Oil Formulation | Avecho Biotechnology | Preclinical |
| Bag APIs | ChemWerth | Approved |
| Oral APIs | ChemWerth | Approved |
| Companion Diagnostics Development | Kiffik Biomedical | Pre-clinical |
| Portfolio of Complex Generics & 505(b)(2) Products | Alvogen | Approved/Commercial |
| Portfolio of 40+ products | Praxgen Pharmaceuticals | Development |
| Drug Repositioning Service | Biovista | Service |
| Custom Control Development | Anchor Molecular | Development/Commercial |
| Portfolio from Steriscience Partnership | Armas Pharmaceuticals | ANDA Development/Filing |